Agree... there is references to phenotyping (albeit early and...

Yes, and it will also support the potential of PTX-100 being pursued as a combo therapy by a prospective partner in any one of a myriad of indications. Phase 1 trials establish whether a drug is safe - clinical activity is a bonus. In the case of our PTX-100 trial/s, both safety and efficacy has been achieved. Fortuitously for our bank balance, the latter was achieved in a rare cancer type of low to unmet need. That gave our company an important foot in the door to prove up the efficacy of PTX-100 in a small group of patients costing far less than would trialling a common cancer type requiring big patient numbers. Its hard to imagine PTX-100 not attracting attention if it gets approval for Phase 2 (esp a registrational trial).

PTX-100 could end up proving akin to those checkpoint inhibitors that have already made it into commercialisation and commonly used in combination trials. We have yet to discover the potential of this technology which is what could make things really interest to see the SP back in 6s. I check the charts and on every timeframe, it looks like its at a favourable turning point. Where are in the that area which Slick earlier suggested as a possible reversal zone to the upside! Sheesh... srsly, I cant' buy more... its too goddam hot outside!

Agree... there is references to phenotyping (albeit early and briefly in the piece/peace.. I never know which) that suggests that our patent application "METHODS OF PRODUCING IMPROVED IMMUNE CELL POPULATIONS" covers both arms of CellPryme including CP-M. Maybe the complexity of CP-A and the different scenarios in which it can be deployed explains the volume of documentation that applies to it.

Thanks for your analysis. I can't say I have taken it all in yet... but hope that I will in time. LOL

In the meantime, we will have of our man, Stuie, also giving us his expert research. Hope there is no pulling the wool over Shell's eyes in the upcoming webinar. I have given up big bucks to not work in the sun today to attend! LOL